Back to Journals » Breast Cancer: Targets and Therapy » Volume 5

Emerging targeted combinations in the management of breast cancer

Authors Lee, Armstrong, Wardley A

Received 20 December 2012

Accepted for publication 4 March 2013

Published 13 August 2013 Volume 2013:5 Pages 61—72

DOI https://doi.org/10.2147/BCTT.S26771

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 2


Rebecca J Lee, Anne C Armstrong, Andrew M Wardley

Department of Medical Oncology, The Christie NHS Foundation Trust, Wilmslow Road, Manchester, UK

Abstract: The number of targeted treatments has risen exponentially over the last few years and is an important concept in the fight against cancer. This review will concentrate on some of the main treatments targeting aberrant pathways which have been tested mainly in the Phase I/II setting. These include human epidermal growth factor receptor 2 inhibitors, drug-antibody conjugates, epidermal growth factor receptor inhibitors, vascular endothelial growth factor inhibitors, reticular activating system, mammalian target of rapamycin and multi-kinase inhibitors. Further knowledge of these pathways and the predictors of response to them will enable personalized medicine to become a reality.

Keywords: breast cancer, targeted therapy, tyrosine kinase, receptor

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]